Organization Overview
Alternative names
autologous lung cancer specific T cells (1 trial)
cervical cancer specific engineered immune effectors (1 trial)
cmv/adv /ebv/bkv specific t cells (1 trial)
gbm-specific car-igt cells (1 trial)
gd2, psma and cd276 car-t cells (1 trial)
hpv specific t cells (1 trial)
muc1/cll1/cd33/cd38/cd56/cd123-specific gene-engineered t cells (1 trial)
multiple sarcoma-specific car-t cells (1 trial)
ovarian cancer specific cytotoxic lymphocytes (1 trial)
personalized neoantigen vaccine (2 trials)
sarcoma-specific car-t cells (1 trial)
Acute Disease (Phase 1)
Adenoviridae Infections (Phase 2)
Breast Neoplasms (Phase 2)
Carcinoma, Ovarian Epithelial (Phase 2)
Carcinoma, Transitional Cell (Phase 2)
Communicable Diseases (Phase 2)
Cytomegalovirus Infections (Phase 2)
Disease (Phase 1)
Epstein-Barr Virus Infections (Phase 2)
Glioblastoma (Phase 2)
Glioma (Phase 1)
Hemophilia A (Phase 2)
Hemophilia B (Phase 1)
Infections (Phase 2)
Leukemia (Phase 2)
Leukemia, B-Cell (Phase 2)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)
Leukemia, Myeloid (Phase 2)
Leukemia, Myeloid, Acute (Phase 2)
Lung Neoplasms (Phase 2)
Lymphoma (Phase 2)
Lymphoma, B-Cell (Phase 2)
Multiple Myeloma (Phase 2)
Mycoses (Phase 2)
Myelodysplastic Syndromes (Phase 1)
Neoplasms (Phase 2)
Neoplasms, Plasma Cell (Phase 2)
Neuroblastoma (Phase 2)
Opportunistic Infections (Phase 2)
Ovarian Neoplasms (Phase 2)
Papilloma (Phase 2)
Preleukemia (Phase 1)
Sarcoma (Phase 2)
Sarcoma, Ewing (Phase 2)
Tuberculosis (Phase 2)
Urinary Bladder Neoplasms (Phase 2)
Uterine Cervical Neoplasms (Phase 2)